Evidence map›Paper›PMID 27901061›Full record

ArticleScientific reports2016

Inter-individual variability and modeling of electrical activity: a possible new approach to explore cardiac safety?

Jean-Yves Le Guennec, Jérôme Thireau, Aude Ouillé, Julien Roussel, Jérôme Roy, Serge Richard, Sylvain Richard, Eric Martel, Pascal Champéroux

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Development ofTranslational and clinical pharmacology · 2024
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jean-Yves Le GuennecInserm U1046-UMR CNRS 9214, Université de Montpellier, 371 avenue du doyen Gaston Giraud, 34295 Montpellier (France).
Jérôme ThireauInserm U1046-UMR CNRS 9214, Université de Montpellier, 371 avenue du doyen Gaston Giraud, 34295 Montpellier (France).
Aude OuilléInserm U1046-UMR CNRS 9214, Université de Montpellier, 371 avenue du doyen Gaston Giraud, 34295 Montpellier (France).
Julien RousselInserm U1046-UMR CNRS 9214, Université de Montpellier, 371 avenue du doyen Gaston Giraud, 34295 Montpellier (France).
Jérôme RoyInserm U1046-UMR CNRS 9214, Université de Montpellier, 371 avenue du doyen Gaston Giraud, 34295 Montpellier (France).
Serge RichardCentre de Recherche Biologique, CERB, Chemin de Montifault, 18800 Baugy (France).
Sylvain RichardInserm U1046-UMR CNRS 9214, Université de Montpellier, 371 avenue du doyen Gaston Giraud, 34295 Montpellier (France).
Eric MartelCentre de Recherche Biologique, CERB, Chemin de Montifault, 18800 Baugy (France).
Pascal ChampérouxCentre de Recherche Biologique, CERB, Chemin de Montifault, 18800 Baugy (France).
Physiologie et Médecine Expérimentale du Coeur et des Muscles · FRInserm · FRUniversité Paris-Sud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Safety pharmacology aims to predict rare side effects of new drugs. We explored whether rare pro-arrhythmic effects could be linked to the variability of the effects of these drugs on ion currents and whether taking into consideration this variability in computational models could help to better detect and predict cardiac side effects. For this purpose, we evaluated how intra- and inter-individual variability influences the effect of hERG inhibition on both the action potential duration and the occurrence of arrhythmias. Using two computer simulation models of human action potentials (endocardial and Purkinje cells), we analyzed the contribution of two biological parameters on the pro-arrhythmic effects of several hERG channel blockers: (i) spermine concentration, which varies with metabolic status, and (ii) L-type calcium conductance, which varies due to single nucleotide polymorphisms or mutations. By varying these parameters, we were able to induce arrhythmias in 1 out of 16 simulations although conventional modeling methods to detect pro-arrhythmic molecules failed. On the basis of our results, taking into consideration only 2 parameters subjected to intra- and inter-individual variability, we propose that in silico computer modeling may help to better define the risks of new drug candidates at early stages of pre-clinical development.

Indexed as

Action PotentialsArrhythmias, CardiacComputer SimulationModels, CardiovascularEndocardiumERG1 Potassium ChannelHumansPotassium Channel BlockersPurkinje CellsERG1 Potassium ChannelKCNH2 protein, humanPotassium Channel Blockers

Identifiers

PMID27901061
PMCPMC5128803
OpenAlexW2559691384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.